{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-022466","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.124391+00:00","generated_at":"2026-06-02T04:15:58.283638+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Prime Medicine Q1 net loss $45.8M; FDA clears IND for CGD Prime Editing therapy","bullets":["Net loss $45.8M (vs $39.4M Q1 2023); cash $224.2M as of March 31, 2024.","FDA cleared IND for PM359 for chronic granulomatous disease—first Prime Editing product to enter clinic.","Phase 1/2 trial planned; initial clinical data expected in 2025.","Appointed Tony Coles, M.D. as senior advisor; brings biopharma leadership.","Presented preclinical data at ASGCT supporting specificity and delivery of Prime Editing platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-022466","json":"https://secwatch.observer/filing/0001628280-24-022466.json","markdown":"https://secwatch.observer/filing/0001628280-24-022466.md","text":"https://secwatch.observer/filing/0001628280-24-022466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024022466/0001628280-24-022466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024022466/prme-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:15:58.283638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9bc6b5a1ab176b3215b67116d83a71be7236fc7","claim":"Prime Medicine, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"today reported financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024022466/0001628280-24-022466-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}